To the Editor Normal neutrophilic activity converts oxygen into free radicals. The resulting Binflammatory hypoxia^protects intestinal epithelium by stimulating mucus production and regulating transcription of pro-and anti-inflammatory genes. In chronic granulomatous disease (CGD); however, these responses fall short [1] . In addition, chronic infection leads to excessive IL-23 production by antigen presenting cells and promotes differentiation of inflammatory Th17 cells [2] . Colitis is seen in ∼50% of CGD patients, especially those with X-linked disease [3] , possibly due to hyper-inflammatory processes such as these.
We followed a 14-year-old boy with X-CGD, diagnosed in infancy after presenting with recurrent cervical lymphadenitis due to Staphylococcus aureus. His neutrophils showed no increase in dihydrorhodamine fluorescence upon stimulation, and a null mutation was genetically identified (Cybb gene, p.Arg290Ter). He developed chronic colitis at age 3, complicated by perirectal abscesses and requiring anal fistulotomy. His weight was consistently below 3% (z-score ∼−5) and he had chronically low albumin (2-2.8 g/L). At age 14, his bone age was 8 years. His severe colitis withstood treatment with azathioprine, methotrexate, 6-mercaptopurine, GM-CSF, hydroxychloroquine, mesalamine, infliximab (stopped due to liver abscess), adalimumab, and corticosteroids (prednisone and budesonide (Entocort-EC)). Recurrent flare-ups necessitated total parenteral nutrition and parenteral, systemic corticosteroids. Biopsies consistently showed chronic active pancolitis with cryptitis, crypt abscesses, and granuloma formation throughout childhood.
Ustekinumab was approved in 2009 by the FDA for psoriasis and psoriatic arthritis. This monoclonal antibody antagonizes binding of IL-12 and IL-23 to their receptors by binding the common p40 subunit of IL-12 and IL-23. A phase 2b trial showed subjects with Crohn's disease benefited from ustekinumab [4] . We provided a subcutaneous dose of ustekinumab 45 mg (∼2 mg/kg) every 2 weeks to determine the maximal benefit of the response to anti-IL-12p40 antagonism, with a switch to monthly dosing after 4 months. Within a month, his cheilitis improved, his appetite dramatically increased, his diarrhea ceased completely, and his weight rose. Over 2 months, his serum albumin rose and reached 3.8 g/L (normal) for the first time in his life. His mild anemia (hemoglobin ∼9 g/dL) prior to therapy improved slightly (10.3 g/dL one year later). He was able to significantly decrease his dose of Entocort-EC from 3 mg three times daily to 3 mg every other day.
He received prophylaxis with clindamycin, trimethoprim/ sulfamethoxazole, and itraconazole; interferon-gamma had been discontinued years before due to an increase in colitic flares. The patient twice developed mucosal inflammation of the nares that grew methicillin-sensitive S. aureus and required treatment with topical retapamulin, oral rifampin, and surgical debridement. Fourteen months after starting ustekinumab, he developed dyspnea, chest pain, and fevers. Chest CT revealed enlarged, necrotic, low-density hilar lymph nodes, and >15 parenchymal mass-like opacities with adjacent ground-glass halos; there was no effusion or pleural thickening. He was admitted and treated with antibiotics Encapsulated summary: Ustekinumab dramatically improved severe colitis in CGD, but may increase risk of infections.
(meropenem), antifungals (caspofungin and voriconazole), and oxygen with rapid defervescence and clinical improvement. Blood cultures did not reveal an organism, an unfortunately common occurrence in CGD [5] . Ustekinumab was discontinued because of this infectious complication. Subsequently, his colitis returned. Intermittent bleeding in the stools (2-3 episodes over 5 months) began approximately 4 months later. There was a significant increase in bleeding and diarrhea 13 months after discontinuation of ustekinumab necessitating an increase in Entocort-EC to 3 mg twice daily. His albumin has been consistently below normal for the past 3 years. Current biopsies show chronic, focally active colitis with granuloma formation, with no evidence of eosinophilia, CMV, acid fast bacilli, or fungi. Pigmented histiocytes were easily identified in the mucosa and submucosa, as is typically seen in CGD-associated colitis.
In summary, therapy with ustekinumab eliminated colitis in this subject, though the improvement was not durable after stopping treatment. In the CGD-associated colitis of humans and murine models, hyper-inflammation has been associated with elevations of interferon gamma, IL-17A, and IL-21, suggesting the involvement of Th17 and Th1 cells [6] [7] [8] . TNF production is also likely important in CGD-associated colitis, and though TNF blockade in CGD reduced colitis, it was associated with fatal complications in two out of five patients in one study [9] . Ustekinumab impedes the development of both Th17 (by blocking IL-23) and Th1 cells (by blocking IL-12), though monoclonal therapy that blocks IL-17A alone merits consideration. In Crohn's disease, the rate of infections was no different between subjects treated with ustekinumab and placebo [10] . However, in CGD-associated colitis, we recommend vigilance while on therapy. A lower dose of 1 mg/kg [10] or less may improve the tradeoff between increasing infection susceptibility and reducing intestinal inflammation.
